| Ciliberto D[10] |
Cancer Biol Ther (2015) |
Targeted therapy vs. conventional therapy |
Favor targeted therapy of anti-angiogenic and HER2 but not EGFR pathway |
RR: favor anti-HER2 agents but not for anti-EGFR and anti-angiogenic agents. |
PFS: favor targeted therapy of anti-angiogenic and HER2 but not EGFR pathway. |
Diarrhea: higher in anti-HER2 agents. Rash: higher in anti-EGFR drugs. |
Targeted therapy showed a significant survival benefit, which can be ascribed to anti-angiogenic and anti-HER2 agents. |
| Iacovelli R[18] |
PLoS One (2014) |
Targeted therapy vs. BSC or traditional chemotherapy |
OS: patients ECOG=0: statistically similar; targeted therapy vs. chemotherapy: favor chemotherapy. In patients with ECOG≥1: targeted therapy vs. BSC: favor targeted therapy; targeted therapy vs. chemotherapy: statistically similar; |
NA. |
NA. |
NA. |
In patients with ECOG-PS = 0, ramucirumab and everolimus did not report a significant survival benefit. Any active therapy over BSC was more effective on patients with ECOG-PS = 1 or more. Patients with symptomatic disease should not be immediately excluded by further lines of therapy. |
| Qi WX[22] |
Tumour Biol (2014) |
Anti-VEGF agents vs. non anti-VEGF agents |
Favor anti-VEGF therapy |
Objective RR: favor anti-VEGF therapy |
RFS: favor anti-VEGF therapy |
Grade 3 or 4 thrombocytopenia, diarrhea, and hypertension: higher in anti-VEGF therapy |
The anti-VEGF therapy offered a significant survival benefit in patients with AGC, especially for those previously treated patients. |
